RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers

References

• Jemal A, Bray F, Ferlay J. Global cancer statistics: 2011. CA Cancer J Clin. 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32:605–644.
   PubMed Web of Science ®Google Scholar
• Bölükbas DA, Meiners S. Lung cancer nanomedicine: potentials and pitfalls. Nanomedicine (Lond). 2015;10:3203–3212.
   PubMed Web of Science ®Google Scholar
• Spitz M, Wu X, Wilkinson A, et al. Cancer of the lung. In: Schottenfeld D, Fraumenni J, editors. Cancer epidemiology and prevention. 3rd ed. New York: Oxford University Press; 2006. p.638–658.
   Google Scholar
• Hamra GB, Guha N, Cohen A, et al. Outdoor particulate matter exposure and lung cancer: A systematic review and meta-analysis. Environ Health Perspect. 2014;122:906–911.
   PubMed Web of Science ®Google Scholar
• Wender R, Fontham ETH, Barrera E, et al. American cancer society lung cancer screening guidelines. CA Cancer J Clin. 2013;63:107–117.
   PubMed Web of Science ®Google Scholar
• Herbst RS, J V H, Lippman SM. Molecular origins of cancer lung cancer. N Engl J Med. 2008;359:1367–1380.
   PubMed Web of Science ®Google Scholar
• Spitz MR, Etzel CJ, Dong Q, et al. An expanded risk prediction model for lung cancer. Cancer Prev Res. 2008;1:250–254.
   PubMed Web of Science ®Google Scholar
• Cassidy A, Myles JP, Van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer. 2008;98:270–276.
   PubMed Web of Science ®Google Scholar
• American cancer society. American cancer society [Internet]. [cited 2018 Jan 2]. Available from: https://www.cancer.org/cancer/lung-cancer.html.
   Google Scholar
• Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer. J Natl Compr Cancer Netw. 2012;10:1236–1271.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244–285.
   PubMed Web of Science ®Google Scholar
• Kalemkerian GP, Akerley W, Bogner P, et al. Small cell lung cancer. J Natl Compr Cancer Netw. 2013;11:78–98.
   PubMed Web of Science ®Google Scholar
• Zakowski MF. Pathology of small cell carcinoma of the lung. Semin Oncol. 2003;30:3–8.
   PubMed Web of Science ®Google Scholar
• Hsu PP, Shaw AT. Lung cancer: a wiley genetic opponent. Cell. 2017;169:777–779.
   PubMed Web of Science ®Google Scholar
• Cooper WA, Lam DCL, O’Toole SA, et al. Molecular biology of lung cancer. J Thorac Dis. 2013;5(Suppl 5):S479–90.
   PubMedGoogle Scholar
• Pendharkar D, Ausekar BV, Gupta S. Molecular biology of lung cancer-a review. Indian J Surg Oncol. 2013;4:120–124.
   PubMedGoogle Scholar
• Villalobos P, Wistuba II. Lung cancer biomarkers. Hematol Oncol Clin North Am. 2017;31:13–29.
   PubMed Web of Science ®Google Scholar
• Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11–22.
   PubMed Web of Science ®Google Scholar
• Sholl LM. Biomarkers in lung adenocarcinoma: a decade of progress. Arch Pathol Lab Med. 2015;139:469–480.
   PubMed Web of Science ®Google Scholar
• Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012;18:6169–6177.
   PubMed Web of Science ®Google Scholar
• L V S, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011;22:2616–2624.
   PubMed Web of Science ®Google Scholar
• Yip PY, Yu B, Cooper WA, et al. Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma. J Thorac Oncol. 2013;8:408–414.
   PubMed Web of Science ®Google Scholar
• S V S, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169–181.
   PubMed Web of Science ®Google Scholar
• Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29:2046–2051.
   PubMed Web of Science ®Google Scholar
• Ricciardi GRR, Russo A, Franchina T, et al. NSCLC and HER2: between lights and shadows. J Thorac Oncol. 2014;9:1750–1762.
   PubMed Web of Science ®Google Scholar
• Bu S, Wang R, Pan Y, et al. Clinicopathologic characteristics of patients with HER2 insertions in non-small cell lung cancer. Ann Surg Oncol. 2017;24:291–297.
   PubMed Web of Science ®Google Scholar
• Chatziandreou I, Tsioli P, Sakellariou S, et al. Comprehensive molecular analysis of NSCLC; clinicopathological associations. PLoS One. 2015;10:e0133859.
   PubMed Web of Science ®Google Scholar
• Bergethon K, Shaw AT, Ignatius Ou S-H, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863–870.
   PubMed Web of Science ®Google Scholar
• Yoshida A, Kohno T, Tsuta K, et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol. 2013;37:554–562.
   PubMed Web of Science ®Google Scholar
• Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non–small-cell lung cancer. J Clin Oncol. 2012;30:4352–4359.
   PubMed Web of Science ®Google Scholar
• Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18:382–384.
   PubMed Web of Science ®Google Scholar
• Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19:1469–1472.
   PubMed Web of Science ®Google Scholar
• Jiang T, Gao G, Fan G, et al. FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis. Lung Cancer. 2015;87:1–7.
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Rodon J, Prat A, et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol. 2014;25:552–563.
   PubMed Web of Science ®Google Scholar
• Larsen JE, Minna JD. Molecular biology of lung cancer: clinical implications. Clin Chest Med. 2011;32:703–740.
   PubMed Web of Science ®Google Scholar
• Raso MG, Wistuba II. Molecular pathogenesis of early-stage non-small cell lung cancer and a proposal for tissue banking to facilitate identification of new biomarkers. J Thorac Oncol. 2007;2:S128–S135.
   PubMed Web of Science ®Google Scholar
• Guo JY, Hsu HS, Tyan SW, et al. Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner. Oncogene. 2017;36:2457–2471.
   PubMed Web of Science ®Google Scholar
• Wood SL, Pernemalm M, Crosbie PA, et al. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014;40:558–566.
   PubMed Web of Science ®Google Scholar
• Raman D, Baugher PJ, Thu YM, et al. Role of chemokines in tumor growth. Cancer Lett. 2007;256:137–165.
   PubMed Web of Science ®Google Scholar
• Tyan S-W, Kuo W-H, Huang C-K, et al. Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PLoS One. 2011;6:e15313.
   PubMed Web of Science ®Google Scholar
• Crawford Y, Kasman I, Yu L, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 2009;15:21–34.
   PubMed Web of Science ®Google Scholar
• Tyan S-W, Hsu C-H, Peng K-L, et al. Breast cancer cells induce stromal fibroblasts to secrete ADAMTS1 for cancer invasion through an epigenetic change. PLoS One. 2012;7:e35128.
   PubMed Web of Science ®Google Scholar
• Hassona Y, Cirillo N, Lim KP, et al. Progression of genotype-specific oral cancer leads to senescence of cancer-associated fibroblasts and is mediated by oxidative stress and TGF-β. Carcinogenesis. 2013;34:1286–1295.
   PubMed Web of Science ®Google Scholar
• Gaudet AD, Fonken LK, Watkins LR, et al. MicroRNAs: roles in regulating neuroinflammation. Neuroscientist. 2018;24:221–245..
   Web of Science ®Google Scholar
• Bakker R, Carthew RW. MicroRNAs make a difference in cardiovascular robustness. Dev Cell. 2017;40:515–516.
   PubMed Web of Science ®Google Scholar
• Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol Mech Dis. 2014;9:287–314.
   PubMed Web of Science ®Google Scholar
• Lin PY, Yu SL, Yang PC. MicroRNA in lung cancer. Br J Cancer. 2010;103:1144–1148.
   PubMed Web of Science ®Google Scholar
• Leidinger P, Keller A, Meese E. Micrornas - important molecules in lung cancer research. Front Genet. 2012;2:104.
   PubMedGoogle Scholar
• Castro D, Moreira M, Gouveia AM, et al. MicroRNAs in lung cancer. Oncotarget. 2017;8:81679–81685.
   PubMedGoogle Scholar
• Hayes J, Peruzzi P, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20:460–469.
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci. 2002;99:15524–15529.
   PubMed Web of Science ®Google Scholar
• Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 2015;81:75–93.
   PubMed Web of Science ®Google Scholar
• Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–524.
   PubMed Web of Science ®Google Scholar
• Bernstein E, Kim SY, Carmell MA, et al. Dicer is essential for mouse development. Nat Genet. 2003;35:215–217.
   PubMed Web of Science ®Google Scholar
• Kumar MS, Lu J, Mercer KL, et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007;39:673–677.
   PubMed Web of Science ®Google Scholar
• Karube Y, Tanaka H, Osada H, et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 2005;96:111–115.
   PubMed Web of Science ®Google Scholar
• Díaz-García CV, Agudo-López A, Pérez C, et al. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification. Carcinogenesis. 2013;34:1031–1038.
   PubMed Web of Science ®Google Scholar
• Chiosea S, Jelezcova E, Chandran U, et al. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res. 2007;67:2345–2350.
   PubMed Web of Science ®Google Scholar
• Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15:321–333.
   PubMed Web of Science ®Google Scholar
• Hata A, Kashima R. Dysregulation of microRNA biogenesis machinery in cancer. Crit Rev Biochem Mol Biol. 2016;51:121–134.
   PubMed Web of Science ®Google Scholar
• Inamura K. Major tumor suppressor and oncogenic non-coding RNAs: clinical relevance in lung cancer. Cells. 2017;6:12–26.
   Web of Science ®Google Scholar
• Inamura K, Ishikawa Y. MicroRNA in lung cancer: novel biomarkers and potential tools for treatment. J Clin Med. 2016;5:36–48.
   Web of Science ®Google Scholar
• Joshi P, Middleton J, Jeon Y-J, et al. MicroRNAs in lung cancer. World J Methodol. 2014;4:59–72.
   PubMedGoogle Scholar
• Legras A, Pécuchet N, Imbeaud S, et al. Epithelial-to-mesenchymal transition and microRNAs in lung cancer. Cancers (Basel). 2017;9:101–129.
   PubMed Web of Science ®Google Scholar
• Chen Y, Lu L, Feng B, et al. Non-coding RNAs as emerging regulators of epithelial to mesenchymal transition in non-small cell lung cancer. Oncotarget. 2017;8:36787–36799.
   PubMedGoogle Scholar
• Xu Q, Sun Q, Zhang J, et al. Downregulation of miR-153 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer. Carcinogenesis. 2013;34:539–549.
   PubMed Web of Science ®Google Scholar
• Kiyohara C, Horiuchi T, Takayama K, et al. Genetic polymorphisms involved in the inflammatory response and lung cancer risk: a case-control study in Japan. Cytokine. 2014;65:88–94.
   PubMed Web of Science ®Google Scholar
• Halappanavar S, Nikota J, Wu D, et al. IL-1 receptor regulates microRNA-135b expression in a negative feedback mechanism during cigarette smoke–induced inflammation. J Immunol. 2013;190:3679–3686.
   PubMed Web of Science ®Google Scholar
• Wang C, Yuan J, Wang C, et al. Anti-inflammatory effects of phyllanthus emblica L on benzopyrene-induced precancerous lung lesion by regulating the IL-1β/miR-101/Lin28B signaling pathway. Integr Cancer Ther. 2017;16:505–515.
   PubMed Web of Science ®Google Scholar
• Lv P, Zhang P, Li X, et al. Micro ribonucleic acid (RNA)-101 inhibits cell proliferation and invasion of lung cancer by regulating cyclooxygenase-2. Thorac Cancer. 2015;6:778–784.
   PubMed Web of Science ®Google Scholar
• Lei Y-M, Zu Y-F, Wang J, et al. Interleukin-1β-mediated suppression of microRNA-101 and upregulation of enhancer of zeste homolog 2 is involved in particle-induced lung cancer. Med Oncol. 2014;32:387.
   PubMed Web of Science ®Google Scholar
• Keller A, Leidinger P, Vogel B, et al. miRNAs can be generally associated with human pathologies as exemplified for miR-144*. BMC Med. 2014;12:224.
   PubMed Web of Science ®Google Scholar
• Keller A, Leidinger P, Borries A, et al. miRNAs in lung cancer - Studying complex fingerprints in patient’s blood cells by microarray experiments. BMC Cancer. 2009;9:353.
   PubMed Web of Science ®Google Scholar
• Del VV, Denti MA. MicroRNA and lung Cancer. In: Santulli G, editor. microRNA: Cancer. Switzerland: Springer International Publishing; 2015. p. 153–177.
   Google Scholar
• Magalhães M, Figueiras A, Veiga F. Smart micelleplexes: an overview of a promising and potential nanocarrier for alternative therapies. In: Grumezescu A, editor. Design and development of new nanocarriers . New York: William Andrew Publishing; 2018. p. 257–291.
   Google Scholar
• Naldini L. Gene therapy returns to centre stage. Nature. 2015;526:351–360.
   PubMed Web of Science ®Google Scholar
• Magalhães M, Farinha D, Mcp DL, et al. Increased gene delivery efficiency and specificity of a lipid-based nanosystem incorporating a glycolipid. Int J Nanomedicine. 2014;9:4979–4989.
   PubMed Web of Science ®Google Scholar
• Keeler A, Elmallah M, Flotte T. Gene therapy 2017: progress and future directions. Clin Transl Sci. 2017;10:242–248.
   PubMed Web of Science ®Google Scholar
• Yin H, Kanasty RL, Eltoukhy AA, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15:541–555.
   PubMed Web of Science ®Google Scholar
• Wang W, Li W. Steinhoff NM and G. Non-viral gene delivery methods. Curr Pharm Biotechnol. 2013;14:46–60.
   PubMed Web of Science ®Google Scholar
• Vachani A, Moon E, Wakeam E, et al. Gene therapy for lung neoplasms. Clin Chest Med. 2011;32:865–885.
   PubMed Web of Science ®Google Scholar
• Portnow J, Synold TW, Badie B, et al. Neural stem cell–based anticancer gene therapy: a first-in-human study in recurrent high-grade glioma patients. Clin Cancer Res. 2017;23:2951–2960.
   PubMed Web of Science ®Google Scholar
• Guan X, Guo Z, Wang T, et al. A pH-responsive detachable PEG shielding strategy for gene delivery system in cancer therapy. Biomacromolecules. 2017;18:1342–1349.
   PubMed Web of Science ®Google Scholar
• Lin M, Gao Y, Diefenbach TJ, et al. Facial layer-by-layer engineering of upconversion nanoparticles for gene delivery: near-infrared-initiated fluorescence resonance energy transfer tracking and overcoming drug resistance in ovarian cancer. ACS Appl Mater Interfaces. 2017;9:7941–7949.
   PubMed Web of Science ®Google Scholar
• Ma K, Fu D, Yu D, et al. Targeted delivery of in situ PCR-amplified Sleeping Beauty transposon genes to cancer cells with lipid-based nanoparticle-like protocells. Biomaterials. 2017;121:55–63.
   PubMed Web of Science ®Google Scholar
• Pi F, Binzel DW, Lee TJ, et al. Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nat Nanotechnol. 2018;13:82–89.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zheng W, Tang R, et al. Gene regulation with carbon-based siRNA conjugates for cancer therapy. Biomaterials. 2016;104:269–278.
   PubMed Web of Science ®Google Scholar
• Urnauer S, Klutz K, Grünwald GK, et al. Systemic tumor-targeted sodium iodide symporter (NIS) gene therapy of hepatocellular carcinoma mediated by B6 peptide polyplexes. J Gene Med. 2017;19:1–14.
   Web of Science ®Google Scholar
• Shukla V, Dalela M, Vij M, et al. Systemic delivery of the tumor necrosis factor gene to tumors by a novel dual DNA-nanocomplex in a nanoparticle system. Nanomed Nanotechnol Biol Med. 2017;13:1833–1839.
   PubMed Web of Science ®Google Scholar
• Hussain S. Nanomedicine for treatment of lung cancer. In: Ahmad A, Gadgeel SM, editors. Lung cancer and personalized medicine: Novel therapies andclinical management. Cham: Springer International Publishing; 2016. p. 137–147.
   Google Scholar
• Fujita Y, Kuwano K, Ochiya T. Development of small RNA delivery systems for lung cancer therapy. Int J Mol Sci. 2015;16:5254–5270.
   PubMed Web of Science ®Google Scholar
• Singh MS, Peer D. RNA nanomedicines: the next generation drugs? Curr Opin Biotechnol. 2016;39:28–34.
   PubMed Web of Science ®Google Scholar
• Bobbin ML, Rossi JJ. RNA interference (RNAi)-based therapeutics: delivering on the promise? Annu Rev Pharmacol Toxicol. 2016;56:103–122.
   PubMed Web of Science ®Google Scholar
• Mansoori B, Shotorbani SS, Baradaran B. RNA interference and its role in cancer therapy. Adv Pharm Bull. 2014;4:313–321.
   PubMedGoogle Scholar
• Wang M, Guo Y, Yu M, et al. Photoluminescent and biodegradable polycitrate-polyethylene glycol-polyethyleneimine polymers as highly biocompatible and efficient vectors for bioimaging-guided siRNA and miRNA delivery. Acta Biomater. 2017;54:69–80.
   PubMed Web of Science ®Google Scholar
• Chitkara D, Singh S, Mittal A. Nanocarrier-based co-delivery of small molecules and siRNA/miRNA for treatment of cancer. Ther Deliv. 2016;7:245–255.
   PubMed Web of Science ®Google Scholar
• Gandhi NS, Tekade RK, Chougule MB. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release. 2014;194:238–256.
   PubMed Web of Science ®Google Scholar
• Mercey O, Popa A, Cavard A, et al. Characterizing isomiR variants within the microRNA‐34/449 family. Febs Lett. 2017;591:693–705.
   PubMed Web of Science ®Google Scholar
• Fehlmann T, Backes C, Alles J, et al. A high-resolution map of the human small non-coding transcriptome. Bioinformatics. 2018;34:1621–1628.
   PubMed Web of Science ®Google Scholar
• Jin L, Zeng X, Liu M, et al. Current progress in gene delivery technology based on chemical methods and nano-carriers. Theranostics. 2014;4:240–255.
   PubMed Web of Science ®Google Scholar
• Lee H-Y, Mohammed KA, Nasreen N. Nanoparticle-based targeted gene therapy for lung cancer. Am J Cancer Res. 2016;6:1118–1134.
   PubMed Web of Science ®Google Scholar
• Zamora-Avila DE, Zapata-Benavides P, Franco-Molina MA, et al. WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16-F10 lung metastases growth. Cancer Gene Ther. 2009;16:892–899.
   PubMed Web of Science ®Google Scholar
• Bonnet ME, Gossart JB, Benoit E, et al. Systemic delivery of sticky siRNAs targeting the cell cycle for lung tumor metastasis inhibition. J Control Release. 2013;170:183–190.
   PubMed Web of Science ®Google Scholar
• Amreddy N, Babu A, Muralidharan R, et al. Polymeric nanoparticle-mediated gene delivery for lung cancer treatment. Top Curr Chem. 2017;375:35–58.
   PubMed Web of Science ®Google Scholar
• Günther M, Lipka J, Malek A, et al. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm. 2011;77:438–449.
   PubMed Web of Science ®Google Scholar
• Lipka J, Semmler-Behnke M, Wenk A, et al. Biokinetic studies of non-complexed siRNA versus nano-sized PEI F25-LMW/siRNA polyplexes following intratracheal instillation into mice. Int J Pharm. 2016;500:227–235.
   PubMedGoogle Scholar
• Yu H, Zou Y, Jiang L, et al. Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles. Biomaterials. 2013;34:2738–2747.
   PubMed Web of Science ®Google Scholar
• Kim J, Kang Y, Tzeng SY, et al. Synthesis and application of poly(ethylene glycol)-co-poly(β-amino ester) copolymers for small cell lung cancer gene therapy. Acta Biomater. 2016;41:293–301.
   PubMed Web of Science ®Google Scholar
• Lee DJ, He D, Kessel E, et al. Tumoral gene silencing by receptor-targeted combinatorial siRNA polyplexes. J Control Release. 2016;244:280–291.
   PubMed Web of Science ®Google Scholar
• Merkel OM, Beyerle A, Librizzi D, et al. Nonviral siRNA delivery to the lung: investigation of PEG-PEI polyplexes and their in vivo performance. Mol Pharm. 2009;6:1246–1260.
   PubMed Web of Science ®Google Scholar
• Yan Y, Zhou K, Xiong H, et al. Aerosol delivery of stabilized polyester-siRNA nanoparticles to silence gene expression in orthotopic lung tumors. Biomaterials. 2017;118:84–93.
   PubMed Web of Science ®Google Scholar
• Shen J, Yin Q, Chen L, et al. Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials. 2012;33:8613–8624.
   PubMed Web of Science ®Google Scholar
• Shen J, Sun H, Xu P, et al. Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles. Biomaterials. 2013;34:1581–1590.
   PubMed Web of Science ®Google Scholar
• Hao S, Yan Y, Ren X, et al. Candesartan-graft-polyethyleneimine cationic micelles for effective co-delivery of drug and gene in anti-angiogenic lung cancer therapy. Biotechnol Bioprocess Eng 2015;20:550–560.
   Web of Science ®Google Scholar
• Sun TM, Du JZ, Yao YD, et al. Simultaneous delivery of siRNA and paclitaxel via a “two-in-one” micelleplex promotes synergistic tumor suppression. ACS Nano. 2011;5:1483–1494.
   PubMed Web of Science ®Google Scholar
• Feldmann DP, Xie Y, Jones SK, et al. The impact of microfluidic mixing of triblock micelleplexes on in vitro/in vivo gene silencing and intracellular trafficking. Nanotechnology. 2017;28:224001.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Ishii T, Zheng M, et al. Multifunctional polyion complex micelle featuring enhanced stability, targetability, and endosome escapability for systemic siRNA delivery to subcutaneous model of lung cancer. Drug Deliv Transl Res. 2014;4:50–60.
   PubMed Web of Science ®Google Scholar
• Yu H, Xu Z, Chen X, et al. Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel. Macromol Biosci. 2014;14:100–109.
   PubMed Web of Science ®Google Scholar
• Zhu L, Perche F, Wang T, et al. Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs. Biomaterials. 2014;35:4213–4222.
   PubMed Web of Science ®Google Scholar
• Zhu X, Xu Y, Solis LM, et al. Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc Natl Acad Sci. 2015;112:7779–7784.
   PubMed Web of Science ®Google Scholar
• Taratula O, Garbuzenko OB, Kirkpatrick P, et al. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release. 2009;140:284–293.
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Iyer AK. Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. Drug Discov Today. 2015;20:536–547.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhao X, Guo C, et al. Aptamer-dendrimer bioconjugates for targeted delivery of miR-34a expressing plasmid and antitumor effects in non-small cell lung cancer cells. PLoS One. 2015;10:1–15.
   Web of Science ®Google Scholar
• Khan OF, Zaia EW, Jhunjhunwala S, et al. Dendrimer-inspired nanomaterials for the in vivo delivery of siRNA to lung vasculature. Nano Lett. 2015;15:3008–3016.
   PubMed Web of Science ®Google Scholar
• Ayatollahi S, Salmasi Z, Hashemi M, et al. Aptamer-targeted delivery of Bcl-xL shRNA using alkyl modified PAMAM dendrimers into lung cancer cells. Int J Biochem Cell Biol. 2017;92:210–217.
   PubMed Web of Science ®Google Scholar
• Bordelon H, Biris AS, Sabliov CM, et al. Characterization of plasmid DNA location within chitosan/PLGA/pDNA nanoparticle complexes designed for gene delivery. J Nanomater. 2011;2011:952060.
   Web of Science ®Google Scholar
• Su WP, Cheng FY, Bin SD, et al. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int J Nanomedicine. 2012;7:4269–4283.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhao H, Jia Y, et al. A novel gene delivery composite system based on biodegradable folate-poly (ester amine) polymer and thermosensitive hydrogel for sustained gene release. Sci Rep. 2016;6:21402.
   PubMed Web of Science ®Google Scholar
• Li J, Zheng C, Cansiz S, et al. Self-assembly of DNA nanohydrogels with controllable size and stimuli-responsive property for targeted gene regulation therapy. J Am Chem Soc. 2015;137:1412–1415.
   PubMed Web of Science ®Google Scholar
• Yan Y, Liu L, Xiong H, et al. Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells. Proc Natl Acad Sci. 2016;113:E5702–E5710.
   PubMed Web of Science ®Google Scholar
• Li P, Liu D, Sun X, et al. A novel cationic liposome formulation for efficient gene delivery via a pulmonary route. Nanotechnology. 2011;22:245104.
   PubMed Web of Science ®Google Scholar
• Jiang L, Li L, He X, et al. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response. Biomaterials. 2015;52:126–139.
   PubMed Web of Science ®Google Scholar
• Koshy ST, Cheung AS, Gu L, et al. Liposomal delivery enhances immune activation by STING agonists for cancer immunotherapy. Adv Biosyst. 2017;1:1600013.
   PubMed Web of Science ®Google Scholar
• Ramesh R, Saeki T, Smyth Templeton N, et al. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther. 2001;3:337–350.
   PubMed Web of Science ®Google Scholar
• Ito I, Ji L, Tanaka F, et al. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther. 2004;11:733–739.
   PubMed Web of Science ®Google Scholar
• Qu MH, Zeng RF, Fang S, et al. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer. Int J Pharm. 2014;474:112–122.
   PubMed Web of Science ®Google Scholar
• Xue W, Dahlman JE, Tammela T, et al. Small RNA combination therapy for lung cancer. Proc Natl Acad Sci. 2014;111:E3553–E3561.
   PubMed Web of Science ®Google Scholar
• Choi SH, Jin SE, Lee MK, et al. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur J Pharm Biopharm. 2008;68:545–554.
   PubMed Web of Science ®Google Scholar
• Dolatabadi JEN, Valizadeh H, Hamishehkar H. Solid lipid nanoparticles as efficient drug and gene delivery systems: recent breakthroughs. Adv Pharm Bull. 2015;5:151–159.
   PubMed Web of Science ®Google Scholar
• Han Y, Zhang P, Chen Y, et al. Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy. Int J Mol Med. 2014;34:191–196.
   PubMed Web of Science ®Google Scholar
• Shi SJ, Zhong ZR, Liu J, et al. Solid lipid nanoparticles loaded with anti-microRNA oligonucleotides (AMOs) for suppression of microRNA-21 functions in human lung cancer cells. Pharm Res. 2012;29:97–109.
   PubMed Web of Science ®Google Scholar
• Yu W, Liu C, Liu Y, et al. Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages. Pharm Res. 2010;27:1584–1596.
   PubMed Web of Science ®Google Scholar
• Conde J, Tian F, Hernández Y, et al. In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials. 2013;34:7744–7753.
   PubMed Web of Science ®Google Scholar
• Li Z, Xiang J, Zhang W, et al. Nanoparticle delivery of anti-metastatic NM23-H1 gene improves chemotherapy in a mouse tumor model. Cancer Gene Ther. 2009;16:423–429.
   PubMed Web of Science ®Google Scholar
• Wu YF, Wu HC, Kuan CH, et al. Multi-functionalized carbon dots as theranostic nanoagent for gene delivery in lung cancer therapy. Sci Rep. 2016;6:21170.
   PubMed Web of Science ®Google Scholar
• Chen Y, Gu H, Zhang DSZ, et al. Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier. Biomaterials. 2014;35:10058–10069.
   PubMed Web of Science ®Google Scholar
• Jones CH, Chen CK, Ravikrishnan A, et al. Overcoming nonviral gene delivery barriers: perspective and future. Mol Pharm. 2013;10:4082–4098.
   PubMed Web of Science ®Google Scholar
• Shi J, Kantoff PW, Wooster R, et al. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20–37.
   PubMed Web of Science ®Google Scholar
• Itakura S, Hama S, Matsui R, et al. Effective cytoplasmic release of siRNA from liposomal carriers by controlling the electrostatic interaction of siRNA with a charge-invertible peptide, in response to cytoplasmic pH. Nanoscale. 2016;8:10649–10658.
   PubMed Web of Science ®Google Scholar
• Toporkiewicz M, Meissner J, Matusewicz L, et al. Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges. Int J Nanomedicine. 2015;10:1399–1414.
   PubMed Web of Science ®Google Scholar
• Ling D, Hackett MJ, Hyeon T. Surface ligands in synthesis, modification, assembly and biomedical applications of nanoparticles. Nano Today. 2014;9:457–477.
   Web of Science ®Google Scholar
• Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. 2006;13:225–234.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Takeshita F, Kuwano K, et al. RNAi therapeutic platforms for lung diseases. Pharmaceuticals. 2013;6:223–250.
   Google Scholar
• Schultheis B, Strumberg D, Santel A, et al. First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J Clin Oncol. 2014;32:4141–4148.
   PubMed Web of Science ®Google Scholar
• Davis ME, Zuckerman JE, Choi CHJ, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464:1067–1070.
   PubMed Web of Science ®Google Scholar
• Nair SK, Hull S, Coleman D, et al. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T- lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer. 1999;82:121–124.
   PubMed Web of Science ®Google Scholar
• Reid G, Kao SC, Pavlakis N, et al. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics. 2016;8:1079–1085.
   PubMed Web of Science ®Google Scholar
• Van Zandwijk N, Pavlakis N, Kao SC, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18:1386–1396.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Sharma AR, Sharma G, et al. Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine. Mol Ther Nucleic Acids. 2017;8:132–143.
   PubMedGoogle Scholar
• Amin A, Dudek AZ, Logan TF, et al. Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J Immunother Cancer. 2015;3:14.
   PubMed Web of Science ®Google Scholar